$CHEV
Charging Robotics Inc.

2023 Q1 Form 10-K Financial Statement

#000101738623000067 Filed on February 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $102.2K
YoY Change 254.88%
% of Gross Profit
Research & Development $40.00K $682.0K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $38.83K $102.2K
YoY Change 244.03% 254.94%
Operating Profit -$38.83K -$102.2K
YoY Change 244.03% 254.94%
Interest Expense $5.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$102.2K
YoY Change 482.78%
Income Tax
% Of Pretax Income
Net Earnings -$38.20K -$102.2K
YoY Change 238.49% 482.9%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$30.54
Diluted Earnings Per Share $0.00 -$30.54
COMMON SHARES
Basic Shares Outstanding 314.4M shares 256.7M shares 27.27K shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $107.1K
YoY Change
Cash & Equivalents $3.159K $107.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.78K $107.1K $107.1K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $74.00K
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $78.78K $107.1K $107.1K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $78.78K $107.1K $107.1K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $52.14K $55.14K
YoY Change 176.52% 192.36%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $65.07K $55.14K $55.14K
YoY Change 192.43% 192.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $65.07K $55.14K $55.14K
Total Long-Term Liabilities $0.00
Total Liabilities $65.07K $55.14K $55.14K
YoY Change 192.43% 192.36%
SHAREHOLDERS EQUITY
Retained Earnings -$1.698M -$1.660M
YoY Change 6.56%
Common Stock $31.44K $31.44K
YoY Change 22.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.72K $51.92K $51.92K
YoY Change
Total Liabilities & Shareholders Equity $78.78K $107.1K $107.1K
YoY Change

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$38.20K -$102.2K
YoY Change 238.49% 482.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$28.91K -$65.94K
YoY Change 54.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$75.00K -$63.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $173.0K
YoY Change
NET CHANGE
Cash From Operating Activities -$28.91K -$65.94K
Cash From Investing Activities -$75.00K -$63.00K
Cash From Financing Activities $173.0K
Net Change In Cash -$103.9K $107.1K
YoY Change -8527.01%
FREE CASH FLOW
Cash From Operating Activities -$28.91K -$65.94K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001459188
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q4 us-gaap Assets Current
AssetsCurrent
usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
usd
CY2022 us-gaap Revenues
Revenues
usd
CY2021 us-gaap Revenues
Revenues
usd
CY2021 us-gaap Other General Expense
OtherGeneralExpense
usd
CY2022 us-gaap Debt Instrument Increase Decrease Other Net
DebtInstrumentIncreaseDecreaseOtherNet
usd
CY2022 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
CY2022 us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-56253
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2274999
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
20 Raul Wallenberg Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv
CY2022 dei Entity Address Country
EntityAddressCountry
IL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
69187
CY2022 dei City Area Code
CityAreaCode
(647)
CY2022 dei Entity Registrant Name
EntityRegistrantName
Fuel Doctor Holdings, Inc.
CY2022 dei Local Phone Number
LocalPhoneNumber
558-5564
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
43772394 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
314406030 shares
CY2022 dei Auditor Name
AuditorName
Liebman Goldberg & Hymowitz, LLP
CY2022 dei Auditor Location
AuditorLocation
Garden City, New York
CY2022 dei Auditor Firm
AuditorFirmId
473
CY2022Q4 us-gaap Assets Current
AssetsCurrent
107064 usd
CY2022Q4 us-gaap Assets
Assets
107064 usd
CY2021Q4 us-gaap Assets
Assets
0 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
52144 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18857 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55144 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18857 usd
CY2022Q4 us-gaap Liabilities
Liabilities
55144 usd
CY2021Q4 us-gaap Liabilities
Liabilities
18857 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2990000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2990000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
314406030 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
314406030 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
256739363 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256739363 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
31441 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
25674 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1680227 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1512994 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1659748 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1557525 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
51920 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18857 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107064 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6869 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5496 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
95300 usd
CY2021 us-gaap Professional Fees
ProfessionalFees
23289 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
102169 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
28785 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-102169 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-28785 usd
CY2022 us-gaap Other General Expense
OtherGeneralExpense
54 usd
CY2021 us-gaap Debt Instrument Increase Decrease Other Net
DebtInstrumentIncreaseDecreaseOtherNet
11248 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102223 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-17537 usd
CY2022 fdoc Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.00
CY2021 fdoc Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.00
CY2022 fdoc Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
257055345 shares
CY2021 fdoc Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
143424295 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-12568 usd
CY2021 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
11248 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-17537 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18857 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
173000 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-102223 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
51920 usd
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-102223 usd
CY2021 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-17537 usd
CY2021 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
11248 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
33287 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13917 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
3000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-2628 usd
CY2021 us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
-5000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65936 usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
173000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
173000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
107064 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107064 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
54 usd
CY2021 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
220000000 shares
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
22000 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_zoB4ukGhmJq1" style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify">Fuel Doctor Holdings, Inc. (“Fuel Doctor” or the “Company”) was incorporated in the state of Delaware on March 25, 2008 as Silver Hill Management Services, inc. On August 24, 2011, the Company changed its name to Fuel Doctor Holdings, Inc.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify">On January 6, 2022, Amitay Weiss, Asaf Itzhaik and Moshe Revach were appointed to fill existing vacancies on the Company’s Board of Directors in accordance with the written consent of majority of directors dated January 6, 2022. None of the newly appointed Directors had a prior relationship with the Company. In addition, on January 6, 2022, Amitay Weiss was appointed as the Chief Executive Officer of the Company and on January 26, 2022, Gadi Levin was appointed Chief Financial Officer of the Company.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 5pt 41.2pt 5pt 16.2pt">On January 7, 2022, Deanna Johnson resigned as an officer and as a director of the Company.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify">On March 11, 2022, Medigus Ltd, an Israeli company traded on NASDAQ (“Medigus”), Charging Robotics Ltd, a wholly owned subsidiary of Medigus (“Charging Robotics”) and the Company signed a non-binding letter of intent for a planned securities exchange agreement. The transaction, if executed, will result in Charging Robotics becoming a wholly owned subsidiary of the Company, and in exchange, Medigus will receive 80% of the issued and outstanding shares of common stock of the Company. Upon closing, Medigus will appoint nominees as officers and directors of the Company. As of the closing, the Company is required to have net cash in an amount of no less than $1.0 million, excluding the Company’s expenses in connection with the contemplated transaction. As of the date of these financial statements this transaction has not been consummated.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify"> </p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify">Charging Robotics is a pre-revenue start-up Israeli private company and has set out to change the way electric vehicles are charged. They are developing a robotic platform for charging vehicles in a wireless and automatic manner. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer energy wirelessly from the robot to the vehicle. The robotic platform is small enough to fit under the vehicle, it automatically positions itself for maximum efficiency charging and returns to its docking station at the end of the charging operation.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify; text-indent: 0.5in"> </p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zPXAy05tUd88" style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify"><b>2.2 Use of Estimates and Assumptions</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 41.2pt 0 16.2pt; text-align: justify"> </p>
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1659748 usd
CY2021Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
300000000 shares
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
3000000000 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2990000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
314406030 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256739363 shares
CY2021 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
220000000 shares
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
22000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
173000 usd
fdoc Private Placement Proposed
PrivatePlacementProposed
270000 usd
CY2022Q4 us-gaap Share Price
SharePrice
0.003
us-gaap Partners Capital Account Units Sold In Private Placement
PartnersCapitalAccountUnitsSoldInPrivatePlacement
57666667 shares
CY2021 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
11248 usd
CY2022 us-gaap Business Development
BusinessDevelopment
30000 usd
CY2021 us-gaap Business Development
BusinessDevelopment
4397 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3000 usd
CY2022Q4 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
20000 usd
CY2022 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.01 pure
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
54 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1660000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
348547 usd
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
327080 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-348547 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-327080 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
580912 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
545134 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
580912 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
545134 usd
CY2023Q1 us-gaap Loans And Leases Receivable Gross Carrying Amount
LoansAndLeasesReceivableGrossCarryingAmount
75000 usd
CY2023Q1 us-gaap Loans And Leases Receivable Ratio Of Nonperforming Loans To All Loans
LoansAndLeasesReceivableRatioOfNonperformingLoansToAllLoans
0.05 pure

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
fdoc-20221231_pre.xml Edgar Link unprocessable
fdoc-20221231_cal.xml Edgar Link unprocessable
fdoc-20221231_lab.xml Edgar Link unprocessable
0001017386-23-000067-index-headers.html Edgar Link pending
0001017386-23-000067-index.html Edgar Link pending
0001017386-23-000067.txt Edgar Link pending
0001017386-23-000067-xbrl.zip Edgar Link pending
exhibit_31-1.htm Edgar Link pending
exhibit_31-2.htm Edgar Link pending
exhibit_32-1.htm Edgar Link pending
exhibit_32-2.htm Edgar Link pending
fdoc-20221231.xsd Edgar Link pending
fdoc_2022dec31-10k.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
fdoc_2022dec31-10k_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fdoc-20221231_def.xml Edgar Link unprocessable